Evidence map›Paper›PMID 37415745›Full record

ArticleOncology research2023

Betulinic acid-mediating miRNA-365 inhibited the progression of pancreatic cancer.

Xin Li, Wenkai Jiang, Wancheng Li, Shi Dong, Yan DU, Hui Zhang, Wence Zhou

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xin LiDepartment of General Surgery, The Second Hospital of Lanzhou University, Lanzhou, 730000, China.
Wenkai JiangThe Second Clinical Medical College, Lanzhou University, Lanzhou, 730000, China.
Wancheng LiThe Second Clinical Medical College, Lanzhou University, Lanzhou, 730000, China.
Shi DongThe Second Clinical Medical College, Lanzhou University, Lanzhou, 730000, China.
Yan DUThe Second Clinical Medical College, Lanzhou University, Lanzhou, 730000, China.
Hui ZhangDepartment of General Surgery, The Second Hospital of Lanzhou University, Lanzhou, 730000, China.
Wence ZhouDepartment of General Surgery, The Second Hospital of Lanzhou University, Lanzhou, 730000, China.
Lanzhou University Second Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The dilemma of pancreatic cancer treatment has become a global challenge. For this reason, effective, feasible, and new medical methods are currently much-needed. Betulinic acid (BA) has been valued as a potential therapy for pancreatic cancer. However, the mechanism by which BA exerts an inhibitory effect on the development of pancreatic cancer remains elusive. Methods: A rat model and two cell models of pancreatic cancer were established, and the effect of BA on pancreatic cancer was verified Results: BA can significantly inhibit the proliferation and invasion of pancreatic cancer cells and promote apoptosis. Conclusion: BA inhibits AKT/STAT3 expression and phosphorylation by modulating miR-365/BTG2/IL-6 expression, and BA inhibits the progression of pancreatic cancer through the aforementioned mechanism.

Indexed as

Immediate-Early ProteinsMicroRNAsPancreatic NeoplasmsTriterpenesAnimalsApoptosisBetulinic AcidCell Line, TumorCell ProliferationHumansInterleukin-6Pentacyclic TriterpenesProto-Oncogene Proteins c-aktRatsTumor Suppressor ProteinsBetulinic AcidBTG2 protein, humanImmediate-Early ProteinsInterleukin-6MicroRNAsMIRN365 microRNA, humanPentacyclic TriterpenesProto-Oncogene Proteins c-aktTriterpenesTumor Suppressor ProteinsBetulinic acidBTG2IL-6miRNA-365Pancreatic cancer

Identifiers

PMID37415745
PMCPMC10319593
OpenAlexW4381955955

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.